Mayo, Shadieya T.
HRN: 15-82-93 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/24/2022
CO-AMOXICLAV 625MG (TAB)
11/24/2022
11/30/2022
ORAL
625 Mg
TID
Community Acquired Pneumonia-Low Risk
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes